Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

Published:2018-07-25 Issue: Volume:8 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Kobold Sebastian,Pantelyushin Stanislav,Rataj Felicitas,vom Berg Johannes

Funder

Krebsliga Schweiz

Novartis Stiftung für Medizinisch-Biologische Forschung

Universität Zürich

Wilhelm Sander-Stiftung

Melanoma Research Alliance

H2020 Marie Skłodowska-Curie Actions

Else Kröner-Fresenius-Stiftung

Elitenetzwerk Bayern

Ludwig-Maximilians-Universität München

European Research Council

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference62 articles.

1. The hallmarks of cancer;Hanahan;Cell,2000

2. Continuous cultures of fused cells secreting antibody of predefined specificity;Kohler;Nature,1975

3. Cancer immunotherapy comes of age;Topalian;J Clin Oncol.,2011

4. Cancer immunotherapy comes of age;Mellman;Nature,2011

5. Evolving role of cetuximab in the treatment of colorectal cancer;Schuch;Cancer Manag Res.,2009

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies;International Journal of Molecular Sciences;2024-07-15

2. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin;Molecular Cancer Therapeutics;2024-04-19

3. Based on the prognosis model of immunogenes, the prognosis model was constructed to predict the invasion of immune genes and immune cells related to primary liver cancer and its experimental validation;Heliyon;2024-04

4. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape;Journal for ImmunoTherapy of Cancer;2024-04

5. Classification of bladder cancer based on immune cell infiltration and construction of a risk prediction model for prognosis;Journal of Zhejiang University (Medical Sciences);2024-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3